Computational Methods for Epigenetic Drug Discovery: A Focus on Activity Landscape Modeling

被引:7
|
作者
Jesus Naveja, J. [1 ,2 ]
Iluhi Oviedo-Osornio, C. [1 ]
Medina-Franco, Jose L. [1 ]
机构
[1] Univ Nacl Autonoma Mexico, Fac Quim, Mexico City, DF, Mexico
[2] Univ Nacl Autonoma Mexico, Fac Med, PECEM, Mexico City, DF, Mexico
关键词
HISTONE DEACETYLASE INHIBITORS; ACTIVITY CLIFF GENERATORS; MOLECULAR-MECHANISMS; LEUKEMIA-CELLS; INDEX;
D O I
10.1016/bs.apcsb.2018.01.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Epigenetic drug discovery is an emerging strategy against several chronic and complex diseases. The increased interest in epigenetics has boosted the development and maintenance of large information on structure-epigenetic activity relationships for several epigenetic targets. In turn, such large databases-many in the public domain-are a rich source of information to explore their structure-activity relationships (SARs). Herein, we conducted a large-scale analysis of the SAR of epigenetic targets using the concept of activity landscape modeling. A comprehensive quantitative analysis and a novel visual representation of the epigenetic activity landscape enabled the rapid identification of regions of targets with continuous and discontinuous SAR. This information led to the identification of epigenetic targets for which it is anticipated an easier or a more difficult drug-discovery program using conventional hit-to-lead approaches. The insights of this work also enabled the identification of specific structural changes associated with a large shift in biological activity. To the best of our knowledge, this work represents the largest comprehensive SAR analysis of several epigenetic targets and contributes to the better understanding of the epigenetic activity landscape.
引用
收藏
页码:65 / 83
页数:19
相关论文
共 50 条
  • [1] Computational methods for drug design and discovery: focus on China
    Zheng, Mingyue
    Liu, Xian
    Xu, Yuan
    Li, Honglin
    Luo, Cheng
    Jiang, Hualiang
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2013, 34 (10) : 549 - 559
  • [2] Exploring the epigenetic drug discovery landscape
    Prachayasittikul, Veda
    Prathipati, Philip
    Pratiwi, Reny
    Phanus-umporn, Chuleeporn
    Malik, Aijaz Ahmad
    Schaduangrat, Nalini
    Seenprachawong, Kanokwan
    Wongchitrat, Prapimpun
    Supokawej, Aungkura
    Prachayasittikul, Virapong
    Wikberg, Jarl E. S.
    Nantasenamat, Chanin
    EXPERT OPINION ON DRUG DISCOVERY, 2017, 12 (04) : 345 - 362
  • [3] Activity landscape of DNA methyltransferase inhibitors bridges chemoinformatics with epigenetic drug discovery
    Jesus Naveja, J.
    Medina-Franco, Jose L.
    EXPERT OPINION ON DRUG DISCOVERY, 2015, 10 (10) : 1059 - 1070
  • [4] Computational methods in drug discovery
    Leelananda, Sumudu P.
    Lindert, Steffen
    BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY, 2016, 12 : 2694 - 2718
  • [5] COMPUTATIONAL METHODS IN DRUG DISCOVERY
    Gupta, Shruti
    Basu, Aparajita
    Jaiswal, Anamika
    Mishra, Nidhi
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2018, 9 (10): : 4102 - 4108
  • [6] Computational Methods in Drug Discovery
    Sliwoski, Gregory
    Kothiwale, Sandeepkumar
    Meiler, Jens
    Lowe, Edward W., Jr.
    PHARMACOLOGICAL REVIEWS, 2014, 66 (01) : 334 - 395
  • [7] Computational Methods for Drug Discovery and Design
    Tropsha, Alexander
    Bajorath, Juergen
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (01) : 1 - 1
  • [8] Drug discovery accelerated by computational methods
    Jorgensen, William L.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [9] Troubleshooting computational methods in drug discovery
    Kortagere, Sandhya
    Ekins, Sean
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2010, 61 (02) : 67 - 75
  • [10] The Computational Methods in Drug Targets Discovery
    Lin, Hao
    CURRENT DRUG TARGETS, 2019, 20 (05) : 479 - 480